Shattuck Labs, Inc. (STTK:NASDAQ) closed at $5.49 on October 23, 2026, down 1.96% on the day. The stock trades 34.1% below its 52-week high of $8.33 and 219.2% above its 52-week low of $1.72. Over the past year, it gained 185.9%. Shattuck Labs, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, STTK closed higher on 128 days (51%). Its best day was January 7, 2026 (+20.60%) and its worst was June 8, 2026 (-14.85%). The stock moved 10% or more in a single session 9 times.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Find more stocks like STTK with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.